Related Experiment Video
Updated: Sep 16, 2025

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring
Published on: May 17, 2024
Pregestational Diabetes Mellitus and Adverse Perinatal Outcomes: A Systematic Review and Meta-Analysis
Dionysios Gazis1, Antigoni Tranidou1, Antonios Siargkas1
13rd Department of Obstetrics and Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Background/Objectives: As the incidence of diabetes mellitus (DM) is increasing rapidly worldwide, it is anticipated that an increasing number of women will enter pregnancy with pregestational diabetes mellitus (PGDM) in the future. Compelling evidence suggests that hyperglycemia in pregnancy is related to multiple adverse perinatal outcomes. This systematic review and meta-analysis aims to assess and quantify the association of PGDM with a range of adverse perinatal outcomes, providing a comprehensive understanding of its impact on pregnancy. Methods: The data sources of this systematic review and meta-analysis were Medline/PubMed, Scopus and Cochrane Library (January 1999 to August 2023), complemented by hand-searching for additional references. Observational studies reporting perinatal outcomes of pregnancies with PGDM diagnosed before pregnancy versus control pregnancies were eligible for inclusion. A systematic review and meta-analysis were conducted as per the PRISMA guidelines. Pooled estimate odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to determine the risk of adverse pregnancy outcomes between PGDM and control pregnancies. Results: The systematic search of the literature yielded 81 observational studies meeting inclusion criteria and in total, 137,237,640 pregnancies were included in the analysis. A total of 19 adverse perinatal outcomes were assessed, revealing a significant association with PGDM. In pregnancies with PGDM there was an increased risk of adverse perinatal outcomes, including gestational hypertension (OR 3.16, 95% CI 2.65-3.77), preeclampsia (OR 4.46, 95% CI 3.94-5.05), preterm delivery (OR 3.46, 95% CI 3.06-3.91), cesarean delivery (OR 3.12, 95% CI 2.81-3.47), induction of labor (OR 2.92, 95% CI 2.35-3.63), macrosomia (OR 2.23, 95% CI 1.76-2.83), LGA neonates (OR 3.95, 95% CI 3.47-4.49), low 5-min Apgar score (OR 2.49, 95% CI 2.07-2.99), shoulder dystocia (OR 3.05, 95% CI 2.07-4.50), birth trauma (OR 1.40, 95% CI 1.22-1.62), polyhydramnios (OR 5.06, 95% CI 4.33-5.91), oligohydramnios (OR 1.61, 95% CI 1.19-2.17), neonatal hyperbilirubinemia (OR 3.45, 95% CI 2.51-4.74), neonatal hypoglycemia (OR 19.19, 95% CI 2.78-132.61), neonatal intensive care unit (NICU) admission (OR 4.54, 95% CI 3.87-5.34), congenital malformations (OR 2.44, 95% CI 1.96-3.04), stillbirth (OR 2.87, 95% CI 2.27-3.63) and perinatal mortality (OR 2.94, 95% CI 2.18-3.98). Subgroup analyses indicated a higher risk of neonatal hypoglycemia, stillbirth and perinatal mortality in T1DM pregnancies compared with T2DM pregnancies. Conclusions: This study provides a robust synthesis of evidence underlying the strong association between PGDM and several adverse perinatal outcomes. Early detection, optimal glycemic control during the periconceptional and pregnancy periods, and proper antenatal care are critical to mitigate these risks.
Background/Objectives: As the incidence of diabetes mellitus (DM) is increasing rapidly worldwide, it is anticipated that an increasing number of women will enter pregnancy with pregestational diabetes mellitus (PGDM) in the future. Compelling evidence suggests that hyperglycemia in pregnancy is related to multiple adverse perinatal outcomes. This systematic review and meta-analysis aims to assess and quantify the association of PGDM with a range of adverse perinatal outcomes, providing a comprehensive understanding of its impact on pregnancy. Methods: The data sources of this systematic review and meta-analysis were Medline/PubMed, Scopus and Cochrane Library (January 1999 to August 2023), complemented by hand-searching for additional references. Observational studies reporting perinatal outcomes of pregnancies with PGDM diagnosed before pregnancy versus control pregnancies were eligible for inclusion. A systematic review and meta-analysis were conducted as per the PRISMA guidelines. Pooled estimate odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to determine the risk of adverse pregnancy outcomes between PGDM and control pregnancies. Results: The systematic search of the literature yielded 81 observational studies meeting inclusion criteria and in total, 137,237,640 pregnancies were included in the analysis. A total of 19 adverse perinatal outcomes were assessed, revealing a significant association with PGDM. In pregnancies with PGDM there was an increased risk of adverse perinatal outcomes, including gestational hypertension (OR 3.16, 95% CI 2.65-3.77), preeclampsia (OR 4.46, 95% CI 3.94-5.05), preterm delivery (OR 3.46, 95% CI 3.06-3.91), cesarean delivery (OR 3.12, 95% CI 2.81-3.47), induction of labor (OR 2.92, 95% CI 2.35-3.63), macrosomia (OR 2.23, 95% CI 1.76-2.83), LGA neonates (OR 3.95, 95% CI 3.47-4.49), low 5-min Apgar score (OR 2.49, 95% CI 2.07-2.99), shoulder dystocia (OR 3.05, 95% CI 2.07-4.50), birth trauma (OR 1.40, 95% CI 1.22-1.62), polyhydramnios (OR 5.06, 95% CI 4.33-5.91), oligohydramnios (OR 1.61, 95% CI 1.19-2.17), neonatal hyperbilirubinemia (OR 3.45, 95% CI 2.51-4.74), neonatal hypoglycemia (OR 19.19, 95% CI 2.78-132.61), neonatal intensive care unit (NICU) admission (OR 4.54, 95% CI 3.87-5.34), congenital malformations (OR 2.44, 95% CI 1.96-3.04), stillbirth (OR 2.87, 95% CI 2.27-3.63) and perinatal mortality (OR 2.94, 95% CI 2.18-3.98). Subgroup analyses indicated a higher risk of neonatal hypoglycemia, stillbirth and perinatal mortality in T1DM pregnancies compared with T2DM pregnancies. Conclusions: This study provides a robust synthesis of evidence underlying the strong association between PGDM and several adverse perinatal outcomes. Early detection, optimal glycemic control during the periconceptional and pregnancy periods, and proper antenatal care are critical to mitigate these risks.
More Related Videos
05:31Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
07:36Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Related Concept Videos
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Teratogenicity
Diabetes: Symptoms, Diagnosis, and Complications
Oral Hypoglycemic Agents: Biguanides and Glitazones